Published in final edited form as:

J Drug Target. 2016 April ; 24(4): 328–339. doi:10.3109/1061186X.2015.1077847.

Immune-tolerant elastin-like polypeptides (iTEPs) and their application as CTL vaccine carriers

Dr. S. Cho[&],

Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, 30 E 2000 S, Salt Lake City, Utah 84112

Prof. Dr. S. Dong,

Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, 30 E 2000 S, Salt Lake City, Utah 84112

Prof. Dr. K. N. Parent, and

Dept. of Biochemistry and Molecular Biology, Michigan State University, 603 Wilson Road, East Lansing, MI 48824

Prof. Dr. M. Chen^{*}

Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, 30 E 2000 S, Salt Lake City, Utah 84112

Abstract

Background—Cytotoxic T lymphocyte (CTL) vaccine carriers are known to enhance the efficacy of vaccines, but a search for more effective carriers is warranted. Elastin-like polypeptides (ELPs) have been examined for many medical applications but not as CTL vaccine carriers.

Purpose—We aimed to create immune tolerant ELPs using a new polypeptide engineering practice and create CTL vaccine carriers using the ELPs.

Results—Four sets of novel ELPs, termed immune-tolerant elastin-like polypeptide (iTEP) were generated according to the principles dictating humoral immunogenicity of polypeptides and phase transition property of ELPs. The iTEPs were non-immunogenic in mice. Their phase transition feature was confirmed through a turbidity assay. An iTEP nanoparticle (NP) was assembled from an amphiphilic iTEP copolymer plus a CTL peptide vaccine, SIINFEKL. The NP facilitated the presentation of the vaccine by dendritic cells and enhanced vaccine-induced CTL responses.

Discussion—A new ELP design and development practice was established. The non-canonical motif and the immune tolerant nature of the iTEPs broaden our insights about ELPs. ELPs, for the first time, were successfully used as carriers for CTL vaccines.

Conclusion—It is feasible to concurrently engineer both immune-tolerant and functional peptide materials. ELPs are a promising type of CTL vaccine carriers.

^{*}Corresponding author. Mingnan.chen@utah.edu.

[&]Current address: Nora Eccles Harrison Cardiovascular Research and Training Institute. 95 S. 2000 E. Salt Lake City, UT 84112
Drs. S. Cho and S. Dong equally contributed to this manuscript.

Keywords

Immune-tolerant elastin-like polypeptide; non-canonical elastin-like polypeptide motifs; cytotoxic T lymphocyte vaccine; vaccine carrier; thermally-induced; reversible; inverse phase transition

Introduction

Vaccines that induce CTL responses are important prophylactic or therapeutic modules against cancer and infectious diseases.^(1–3) Using carriers to promote these vaccines' delivery to antigen presenting cells is a strategy to enhance the potency of the vaccines.^(4, 5) While various natural and synthetic materials have been tested as building materials of CTL vaccine carriers,^(6, 7) among them, only virus-like particles (VLPs) have been approved for clinical use to facilitate CTL responses,⁽⁵⁾ a contrast suggesting a need to further search for suitable vaccine carrier materials.

Elastin-like polypeptides (ELPs) share the same chemical nature, protein, with VLPs. ELPs can also self-assemble into nanoparticles (NPs) of a similar size as VLPs.⁽⁸⁾ Besides these similarities to VLPs, ELPs have several additional features appealing to vaccine delivery. (1) The protein-or peptide-based CTL vaccines, potentially, can be fused together with ELPs using genetic engineering approach; the resultant fusion proteins may be easily reproduced in *E.coli* or other expression systems similar to some existing ELP fusions.^(9, 10) (2) When the vaccines are loaded to the carriers using the genetic engineering approach, the copy numbers of the vaccines and their cleavage sites from the carriers are well defined and precisely adjusted to improve the potency of vaccines.^(11–13) (3) The signature property of ELP – the reversible, thermally (or ion)-induced, inverse phase transition – is transferable to ELP-protein fusions and possibly to iTEP-vaccine fusions;⁽¹⁴⁾ The fusions can thus be simply purified by cycling the transition. Although having these appealing features, ELPs have not been reported as CTL vaccine carriers to date. We, thus, explored the possibility of using ELP nanoparticles as CTL vaccine carriers in this study. There were evidences showing that humorally immunogenic carriers jeopardize the potency of their CTL vaccine payloads.^(15–17) Therefore, we sought to use humorally tolerant ELPs as CTL vaccine carriers. Among reported ELPs, a few have been confirmed as immune tolerant while others have been proven immunogenic.^(18–22) These immune tolerant ELPs, however, do not offer the required hydrophobicity and length to form NPs. This limitation prompted us to create new immune tolerant ELPs to meet the vaccine delivery need.

Polypeptide materials, including ELPs, have typically been invented and optimized for physicochemical properties such as their phase transition property, and their immunogenicity was considered only after their physicochemical properties were established. Such practice, however, bears the risk that an ELP with a well-characterized function may indeed become valueless due to its later-discovered adverse immunogenicity.^(23, 24) Thus, we employed a new ELP development practice that places equal weight on ELP's phase transition feature and immunogenicity from the beginning of the development.

Using the new practice, we invented four sets of novel ELPs whose sequences happened to be non-canonical to ELPs' typical "V-P-G-X-G" motif.^(25, 26) We termed these novel ELPs as iTEPs to underscore our new ELP engineering practice. We found all four sets of iTEPs possessed the desired transition property and were tolerated by mouse humoral immunity. We further paired two iTEPs that were opposite in hydrophobicity to make an amphiphilic diblock copolymer. The copolymer, when fused with a model CTL peptide vaccine, SIINFEKL, self-assembled into a NP. The NP enhanced the presentation of the vaccine by dendritic cells (DCs) and increased the strength of the vaccine-induced CTL response. Our results suggest that iTEPs developed with this new practice are suitable for CTL peptide vaccine carriers.

Method

Construction of iTEP expression plasmids

The genes encoding iTEPs were synthesized on a modified pET25b(+) vector using a reported method with some modifications.⁽²⁷⁾ First, a pET25b(+) vector was modified by inserting a double-stranded DNA at the vector's XbaI and BamHI endonuclease restriction sites. The inserted DNA was assembled by annealing together two complementary oligonucleotides, pET25-F and pET25-R (Table S1) (Eurofins Genomics, USA). The insertion of this DNA introduced two new restriction sites for BseRI and AcuI, and an in frame stop codon to the pET25b(+) vector. Second, genes that encoded subunits of iTEP_A: (GVLPGVG)₄, iTEP_B: (GAGVPG)₅, iTEP_C: (VPGFGAGAG)₃, and iTEP_D: (VPGLGAGAG)₃ were generated by annealing the sense and antisense oligonucleotides of these genes together (Table S1). Third, these iTEP genes were inserted to the modified pET25b(+) vector at its BseRI site. Finally, iTEP genes were extended to desired lengths through the following method. Specifically, the modified vector harboring iTEP genes was digested by two sets of enzymes, respectively. The first set includes AcuI, ApaI, and BglII; the second set includes BseRI and ApaI. Then, two DNA fragments that were from the two sets of digestions and contained iTEP genes were isolated and ligated together using T4 DNA ligase to create a new iTEP expression vector. The vector was transformed into DH5α for its amplification. The lengths of iTEP genes which dictated repeat numbers of iTEP building blocks were confirmed by an XbaI and BamH I double digestion and the followed agarose gel analysis. This PRE-RDL process was repeated as desired to generate iTEP genes with designed lengths. The final iTEP genes were verified by DNA sequencing in combination with an endonuclease digestion approach (Genewiz, USA).

The iTEPs used as representatives for this study were: iTEP_A having 28 repeats of GVLPGVG, iTEP_B having 70 repeats of GAGVPG, iTEP_C having 21 repeats of VPGFGAGAG, and iTEP_D having 96 repeats of VPGLGAGAG. iTEP_C which has an odd number of repeat was generated unexpectedly. iTEPs with the above lengths were used for this study primarily because they can be expressed from E.coli and their transition temperature, with or without salt, are between ambient temperature and 60 °C so that it is operationally possible to purify them by cycling the transition. In addition, these sizes of iTEP are in range of natural proteins so that we can study the immunogenicity of iTEPs as proteins instead of peptides.

The gene encoding an amphiphilic fusion, iTEP_B-iTEP_A, was generated by linking iTEP_B and iTEP_A genes together using the PRe-RDL method.⁽²⁷⁾ The gene encoding a fusion, iTEP_B-iTEP_A-pOVA was generated in a similar manner using a gene of pOVA (Table S1). It is noteworthy that pOVA has two copies of a CTL epitope, SIINFEKL.⁽²⁸⁾ There was one natural flanking residue on the each side of SIINFEKL. The actual amino acid sequence of pOVA is ESIINFEKLTESIINFEKLT.

Production and purification of iTEPs and iTEP fusions

Competent BL21(DE3) *E. coli* cells (EMD Chemicals, Inc. USA) were transformed with the pET25b(+) expression vector bearing iTEP or iTEP fusion genes. The single colony transformant was grown in TB media containing 100 µg/ml ampicillin for 24 hours at 37 °C. After the growth, *E. coli* cells were collected as a pellet by centrifugation for 25 minutes at $4,816 \times g$ and 4 °C. The cell pellet was then resuspended in phosphate buffered saline (PBS) and lysed by sonication for 3 minutes/L culture (sonication pulse rate: 10 seconds on and 30 seconds off). Later, 10% of polyethylenimine (PEI) was added to the cell lysate to precipitate *E. coli* DNA, and the precipitant was removed by centrifugation for 15 minutes at $21,000 \times g$ and 4 °C. Lastly, iTEPs or iTEP fusions were purified from the supernatant via inverse transition cycling (ITC) as described previously.⁽²⁹⁾ The purity of iTEP was assessed by SDS-PAGE using copper staining.⁽³⁰⁾

Endotoxin removal for iTEPs and iTEP fusions

Endotoxin of iTEPs or iTEP fusions were removed using Pierce High Capacity Endotoxin Removal Resin (Thermo Scientific, USA) following the manufacturer's instruction. The endotoxin level was determined by Limulus Amebocyte Lysate (LAL) PYROGENT Single Test Vials (Lonza, USA). Final endotoxin levels in these samples were below 0.25 EU per mg protein.

Characterization of thermally-induced, reversible, inverse phase transition of iTEPs and the iTEP_B-iTEP_A-pOVA fusion

The phase transitions of iTEP or iTEP fusions were characterized by turbidity changes of sample solutions as a function of temperature. Specifically, the optical density at 350 nm (OD₃₅₀) of a sample solution was monitored using an UV-visible spectrophotometer equipped with a multi-cell thermoelectric temperature controller (Cary 300, Varian Instruments, Walnut Creek, CA) while the solution was heated from 20 °C to 80 °C and then cooled to 20 °C at a rate of 1 °C/min. The maximum first derivative of the turbidity curve of a sample was identified. The transition temperature (T_t) of the sample is the temperature that corresponds to the maximum derivative.

Characterization of the size of iTEP_B-pOVA and iTEP_B-iTEP_A-pOVA fusions

The particle size distribution of the iTEP fusions was determined by dynamic light scattering (DLS) using a Zetasizer Nano-ZS instrument (Malvern Instruments, Malvern, UK) as previously described.⁽²⁹⁾ The fusions were prepared at 5 µM and 25 µM in PBS and equilibrated at 37 °C for the measurement. The reported results represented the average particle size by number.

Negative-stain, transmission electron microscopy of the iTEP_B-iTEP_A-pOVA fusion

Small, 3.5 μ L aliquots of assembled particles (50 μ M) were applied to a continuous carbon support film (Ted Pella, Redding, CA). The sample was briefly washed with distilled water and then stained with 1% aqueous uranyl acetate. Micrographs were recorded on a DE-20 camera (Direct Electron, LP, San Diego, CA) equipped with a 5120 $\times$ 3840 Direct Detection Device (DDD®) sensor in a JEOL 2200FS microscope at a nominal magnification of 30,000 (1.72 Å per pixel) at an acceleration voltage of 200 keV.

Immunization of iTEPs and collection of immune sera

All animal studies followed an approved protocol by the Institutional Animal Care and Use Committee (IACUC) at the University of Utah. C57BL/6 mice were immunized twice at their right hocks with iTEPs at a dose of 100 μ g/mouse. The two immunizations had a 2 week interval. At 1 week after the second immunization, 100 μ L blood was collected from each immunized mouse. The blood samples were allowed to sit for 30 minutes to one hour at room temperature to clot. Sera were collected from the blood samples after the samples were spun for 10 min at 14,000 rpm at 4 °C. The sera were kept at –80 °C before an analysis of the titers of iTEP-specific IgG.

Determination of IgG titers by ELISA

96-well ELISA plates were coated overnight at 4 °C with 100 μ L/well of capture antigens (20 μ g/ml corresponding iTEPs, ovalbumin (OVA), or MSA). Plates were washed with PBS–0.02% Tween 20 (PBST) buffer and blocked with 200 μ L/well of PBST buffer containing 1% BSA for 1 hour at room temperature. Mouse sera were serially diluted in the PBST–1% BSA buffer and added at 100 μ L/well into the 96-well plate. The plates were incubated at 4 °C overnight. After thoroughly washing with PBST, 100 μ L/well of 1 μ g/mL detection antibody (horseradish peroxidase-conjugated anti-mouse IgG) was added, and plates were incubated for 1 hour at room temperature under continuous shaking. After washing with PBST, 100 μ L/well of tetramethylbenzidine (TMB) substrate solution was added for 15–30 minutes with continual shaking. The reaction was stopped with 100 μ L/well of 1 M H₂SO₄. Plates were read at OD 450 nm (minus 570 nm for wavelength correction).

The end point titer of a serum IgG was defined as the reciprocal of the higher serum dilution which OD value from the ELISA assay is higher than a statistically valid cutoff. The titer results were expressed as IgG titers (Log10) for each sample. The cutoff was established for individual ELISA assay that utilize a given capture antigen. So the cutoffs may be different for distinct capture antigens. Specifically, the cutoff was obtained by using PBS (negative control)-immunized serum to perform ELISA in the corresponding antigen-coated wells. The value of the cutoff was calculated using the following equation:⁽³¹⁾

$$\text{Cutoff} = \bar{X} + SDt \sqrt{1 + (1/n)}$$

where $\bar{X}$ is the mean absorbance readings of independent PBS control sera, SD is the standard deviation of the readings, n is the number of independent PBS controls (mouse

samples), t is the $(1 - \alpha)$ th percentile of the one-tailed t -distribution with $\nu = n - 1$ degrees of freedom.

Presentation of the CTL epitope, SIINFEKL, by DCs

Cells of a murine DC line (DC2.4, a gift from K. Rock)⁽³²⁾ were plated at $2.5 \times 10^5/500\mu\text{L}$ /well in 24-well plates. 500 μL of OVA, SIINFEKL peptide, or iTEP_B-iTEP_A-pOVA NP (iTEP-pOVA NP hereafter) were dissolved in cell culture media and added to the wells containing DCs. The cells were further cultured for 16 hrs at 37 °C with 5% CO₂ before they were collected and washed with PBS. The MHC class I complex, H-2k_b/SIINFEKL presented on DC surface was stained with a PE-tagged monoclonal antibody 25-D1.16 (Biolegend, 1:100 dilution) and quantified with flow cytometry (5×10^4 events collected per sample). The data are presented as MFI normalized to the MFI of untreated DC2.4 cells.

B3Z CD8+ T cell hybridoma activation assay

B3Z cells (a gift from N. Shastri) are a CD8+ T-cell hybridoma engineered to secrete β -galactosidase when their T-cell receptors are engaged with an SIINFEKL:H2K^b complex.⁽³³⁾ To do this assay, 1×10^5 DC2.4 cells/well were set in 96-well plates. OVA, SIINFEKL peptide, and iTEP-pOVA NP at indicated concentrations were loaded into the cell culture for 16 hours and then washed away. 1×10^5 B3Z cells/well were added to the DC2.4 cell culture and co-cultured with DC2.4 cells for 24 hours. The cells were washed with PBS before 100 μL of lysis buffer (PBS with 100 mM 2-mercaptoethanol, 9 mM MgCl₂, 0.125% NP-40) together with 0.15 mM chlorophenol red β -galactoside were added into the wells. After the plates were incubated at 37 °C for 4 hours, the reaction was stopped with 50 μL /well of 15mM EDTA and 300 mM glycine. The OD at 570 nm was measured and the OD at 630 nm was used as reference. The OD was used as an indicator as activation status of B3Z cells.

in vivo CTL response by ELISPOT IFN- γ assay

C57BL/6 mice were immunized subcutaneously with each immunogen (2 nmol SIINFEKL equivalents per mouse) together with incomplete Freund's Adjuvants (IFA; Sigma, USA) at their left flanks. The immunization was repeated at their right flanks 1 week later. At 10 days after the second immunization, mice were sacrificed, and the spleens were harvested. The spleens of the sacrificed mice were teased into single-cell suspensions and filtered through nylon mesh (40 μm). Red blood cells were lysed by Ammonium-Chloride-Potassium (ACK) lysing buffer. The washed and resuspended single cells were counted using Contess™ Automated Cell Counter (Invitrogen, USA). Splenocytes ($8 \times 10^6/\text{mL}$) were incubated in RPMI-1640 medium supplemented with 10% heat inactivated fetal calf serum, 2 mM glutamine, 100 units/mL penicillin and 100 $\mu\text{g}/\text{mL}$ streptomycin (Invitrogen, USA), in a 14mL polypropylene tissue culture tube for 48 hours, with or without SIINFEKL peptide (2.5 $\mu\text{g}/\text{mL}$). The cells were then washed and recounted. 2×10^5 live cells in 100 μL medium were then loaded into wells of 96-well Filtration plates (Millipore, USA) coated with 5 mg/mL of capture anti-mouse IFN- γ mAb (Clone: R4-6A2, Biolegend, USA). Triplicates were set up for each condition. Cells were discarded after 24 hours of culture and the wells were incubated with 2 mg/mL of detectionbiotinylated, anti-mouse IFN- γ mAb

overnight (Clone: XMG1.2-Biotin, Biolegend, USA). After the unbound antibodies were washed away from the wells, the bound antibodies were detected using horseradish peroxidase (HRP Avidin, Biolegend, USA) together with 3-amino-9-ethyl-carbazole (AEC) substrate (Sigma, USA). The membranes on the bottom of the wells were peeled off, and color spots on the membrane were scanned. The spots were automatically counted using ImageJ software.

3. Results

3.1 Design of immune-tolerant elastin-like polypeptides (iTEPs)

The iTEPs were designed as polymers of peptides derived from elastin. One critical criterion of these iTEPs is that they should be humorally tolerant in both mice and humans, a feature that may facilitate their preclinical and clinical applications. For a polypeptide to be humorally immunogenic, it must contain at least one epitope to bind with B cell receptors (BCRs) and another epitope to bind first with the MHC class II complex, and then with a cognate T cell receptor (TCRs) on CD4+ T cells.^(34–36) By the same token, a humorally tolerant polypeptide should not contain TCR or BCR epitopes. In this study, homologous peptide sequences between human and mouse elastins were chosen as the monomers of iTEPs. These homologous sequences should intrinsically not bind with BCRs and TCRs of human and mouse; otherwise they would induce autoimmune responses (Figure 1).

Because iTEPs are polymers of elastin-derived peptides, the polymerization may introduce junction sequences that are exogenous to humans and mice, and these junction sequences are potentially humorally immunogenic. To diminish the possible immunogenicity, we utilized two strategies. First, we used the homologous peptides that repeat themselves within human and mouse elastins as the monomers of iTEPs (see iTEP_C and iTEP_D, Figure 1), so there are no extrinsic junction sequences in iTEPs. Further, the repeats have 18 residues and are longer than the typical length of MHC class II-restricted TCR epitopes (13–17 residues) and linear BCR epitopes (4–6 residue).^(37, 38) Thus, the repeats are long enough to be used naturally to negatively select and deplete the BCRs and TCRs binding with them during lymphocyte development.⁽³⁹⁾ Consequently, no human and mouse BCRs or TCRs should bind with these repeats. iTEPs that are polymerized from these repeats, therefore, should be low- or non- immunogenic.

Our second strategy was applied when exogenous junction sequences were unavoidable. In this case, we had two criteria for monomers of iTEPs: one, they should be long homologous peptides from the elastins; two, they should be flanked by Glycyls at both ends (iTEP_A and iTEP_B, Figure 1). By using the longer monomers rather than shorter ones, we lowered numbers of the junction sequences in iTEPs of a certain length. Potentially, this might lower immunogenicity of iTEPs, because the epitope density is a critical factor for the strength of immune responses.^(40–42) The Gly-flanked monomers resulted in a high frequency of Glycyls inside the junction sequences, which could mitigate the immunogenicity of the junction sequences as Glycyl had been shown to silence BCR epitopes.^(43, 44) With the second strategy, we expected iTEPs to have a low immunogenicity.

In order for our iTEPs to have the phase transition property of ELPs, all monomers of iTEPs were designed to contain only one proline and at least one valine (Figure 1). We hypothesized that this criterion is sufficient to render iTEPs the transition property, based on our studies of published ELP sequences.⁽²¹⁾ It is noted that no iTEP monomers that we eventually created have the canonical motif, VPGXG, of ELPs,⁽⁴⁵⁾ which is not unexpected since the canonical motif was not a part of our iTEP design criteria.

3.2 Cloning and expression of iTEPs

iTEPs were produced and purified as recombinant proteins from *E. coli*. Their coding genes for iTEPs were constructed and elongated using a modified Pre-RDL method (Figure 2A).⁽²⁷⁾ The coding genes were confirmed by DNA sequencing in combination with endonuclease digestion approach. The agarose gel results (Figure 2B) confirmed the sizes of the coding genes: iTEP_A (600 bps), iTEP_B (1272 bps), iTEP_C (579 bps), and iTEP_D (2604 bps). Purity and sizes of the iTEPs after purification were confirmed by SDS-PAGE (Figure 2C). It is noteworthy that iTEP_B did not negatively stain as well as other iTEPs, probably due to its hydrophilic yet uncharged nature (below). The nature may hinder the emulsification of SDS around the iTEP, thus the iTEP can neither focus well on the gel nor have enough SDS to prevent formation of copper complex *in situ*.^(46, 47) As a result, this iTEP appears as a smear on a copper-stained SDS-PAGE.

3.3 Thermally-induced, reversible phase transition of iTEPs

All four iTEP sets have variants displaying the phase transition feature (Figure 3A–E). The associated inverse transition temperatures (T_t) of these iTEPs are summarized together with their sequences and molecular weights in Table 1. iTEP_B displayed much higher T_ts than the other three iTEPs. Specifically, iTEP_B did not form coacervates in the tested temperature range (20–80 °C) in H₂O, while the others formed coacervates between 29–38 °C (Figure 3B versus Figure 3A, C, D). To achieve a thermally-induced phase transition of iTEP_B, we had to perform the experiment in a solution containing 2.5M NaCl (Figure 3F). The high T_t of iTEP_B suggests it is much more hydrophilic than the other three iTEPs. Thus, among the four sets of iTEPs, we attained both hydrophilic and hydrophobic ones (Table 1).

An intriguing observation was made when T_ts of iTEP_C and iTEP_D (Figures 3C and D) were compared at two different concentrations, 5 and 25 μM. At 25 μM, iTEP_C had a lower (heating) T_t than iTEP_D, 35.7 °C versus 38.6 °C; at 5 μM, iTEP_C, however, displayed a higher T_t than iTEP_D, 50.5 °C versus 42.3 °C. The two iTEPs are similar to each other with only two differences: (1) the fourth residue of their repeat units, Phe for iTEP_C versus Leu for iTEP_D (Figure 1), and (2) the number of repeat units, 21 for iTEP_C versus 96 for iTEP_D (Table 1). While the first difference predisposes iTEP_C to a lower T_t than iTEP_D, the second difference predisposes iTEP_C to a higher T_t than iTEP_D.^(48, 49) At 25 μM, the impact of the fourth residue difference apparently prevailed over the impact of the repeat number difference; at 5 μM, vice versa. Thus, concentration changes of iTEPs apparently altered the impact of the two differentiating factors but at different scales. A clear delineation of this interesting observation will require a systematic study with two sets of iTEP_C and iTEP_D with comparable lengths.

3.4 Humoral immunogenicity of iTEPs

Mice were immunized with the four iTEPs, a positive control (OVA), and a negative control (mouse serum albumin, MSA) (Figure 4A). As expected, the OVA-immunized mice displayed a strong humoral response to OVA with a median antibody titer of 2.6×10^7 ; MSA-treated mice showed a very low humoral response, evidenced by a median antibody titer of 6.2×10^2 (Figure 4B). Among the four iTEPs, the plasma of iTEP_A-, iTEP_C-, and iTEP_D-treated mice were negative for any iTEP-specific antibody after the plasmas were diluted by 100 times and up (Figure 4C, 4E, 4F), so their median titers should be less than or equal to 100 (Figure 4B). The plasma of iTEP_B-treated mice had a median antibody titer of 4.5×10^2 (Figure 4B, 4D). Because all of the iTEPs' titers are indifferent to that of MSA, but significantly different to the titer of OVA, we concluded that all iTEPs are humorally immune-tolerated by mice as MSA.

It has been reported that the aggregation of peptide and proteins could drastically increase their humoral immunogenicity.^(50, 51) However, the aggregation statuses of the iTEPs did not appear to affect their immunogenicity. First, soluble and aggregate forms of iTEP_C did not show different immunogenicity (Figure S1). Second, all tested iTEPs are non-immunogenic despite the fact that iTEP_A, iTEP_C, and iTEP_D were injected as aggregates, while iTEP_B was injected as a soluble molecule for the immunization.

3.4 NPs self-assembled from iTEP-CTL vaccine fusions

The hydrophobic iTEP_A, hydrophilic iTEP_B, and pOVA were fused together to form an amphiphilic iTEP copolymer: iTEP_B-iTEP_A-pOVA (Figure 5A). This pair of iTEPs was used to construct the amphiphile because the both iTEPs gave good yields, and we expected the amphiphile would also have a good yield. Indeed, we were able to purify about 200 mg of amphiphilic fusion from one liter of culture (Figure 5B). The fusion displayed a micelle-like NP structure, evidenced by its two-step phase transition profile (Figure 5C).⁽⁸⁾ The NP structure of the fusion was also confirmed by DLS (Figure 5D), as well as electron microscopy (Figure 5E). According to DLS data, the NPs have a mean diameter of 81.2 ± 14.2 nm at 5 μ M and 71.9 ± 20.8 nm at 25 μ M (Figure 5D). Contrariwise, iTEP_B-pOVA, a fusion of the hydrophilic iTEP_B and the vaccine, is soluble and does not form particles. The size of this fusion is less than 10 nm as measured by DLS (Figure 5D).

3.5 Immune responses induced by the iTEP-pOVA NP

First, we tested whether the iTEP-pOVA NP promotes processing and presentation of SIINFEKL by DCs. The NP, soluble iTEP_B-pOVA fusion, as well as OVA was incubated with DCs, respectively. The surface presentation of SIINFEKL by DCs was detected by an antibody that can recognize the SIINFEKL/H-2K^b complex. Although all of the above incubations led to presentations of the epitope on the DCs' surface, DCs incubated with the NP presented significantly more SIINFEKL epitopes than DCs with OVA or iTEP_B-pOVA (Figure 6A). It is noteworthy that free SIINFEKL peptide resulted in much stronger SIINFEKL presentation by DCs than the NP, OVA, or iTEP_B-pOVA fusion (data not shown). The result was likely caused by a direct exchange between SIINFEKL with those epitopes that were originally present on the DCs' surface. Thus, the presentation of free SIINFEKL peptide by DCs does not need an antigen processing by the cells. Consequently,

the result of free SIINFEKL peptide is not comparable with the results of other forms SIINFEKL-containing antigens which require antigen processing before SIINFEKL is presented.

Next, we examined if the improved presentation of SIINFEKL by iTEP-pOVA NP-treated DCs can lead to a more efficient activation of SIINFEKL-restricted CD8 cells. We used B3Z cells as target cells to perform a CD8⁺ T cell activation assay. The B3Z cells that were co-cultured with the NP-pretreated DC2.4 cells were several fold more active than the B3Z cells co-cultured with the DC2.4 cells pretreated with other antigens. Specially, NP/DC-treated B3Z cells were 4.38, 3.81, or 2.9 fold more active than DC-treated B3Z cells, OVA/DC-treated B3Z cells, and iTEP_B-pOVA/DC-treated B3Z cells, respectively (Figure 6B). As a positive control, B3Z cells co-cultured with DC2.4 cells pre-pulsed with free SIINFEKL peptide showed the highest activity among all treatments (Figure 6B). This result is consistent with the observation that DCs much more efficiently presented SIINFEKL when the peptide was incubated with DCs as a free form.

Last, we examined whether the enhanced vaccine presentation and CTL activation caused by the iTEP-pOVA NP can translate into elevated CTL responses *in vivo*. To this end, we subcutaneously immunized C57BL/6J mice twice with PBS, OVA, SIINFEKL peptide, or the NP and collect splenocytes from these mice. We then quantified SIINFEKL-restricted, activated splenocytes using an INF- γ -based ELISPOT assay; those splenocytes released INF- γ should be SIINFEKL-restricted CTLs. Both OVA and the free peptide immunization lead to a boost of the number of CTLs compared to the PBS control. However, the NP-immunized mice had a much higher number of the CTLs (averagely 105 spots per million seeded splenocytes) than both OVA- and SIINFEKL peptide-immunized mice (averagely 61 and 60 spots per million seeded splenocytes, respectively) (Figure 6C). It is interesting that the free peptide did not induce the strongest SIINFEKL-specific CTL response *in vivo* even though it had the highest response *in vitro*, suggesting that the CTL peptide vaccines need a supportive carrier. The deficiency of the free peptide vaccine might be due to a fast clearance of the peptide after its immunization; thus the vaccine had very limited access to dendritic cells and other antigen presenting cells.

Discussion

In this study, we took an initiative to test a new ELP design and engineering practice that emphasizes physicochemical properties as well as immunogenicity of the ELPs from the very beginning of ELP design. We designed and generated four families of novel ELPs, termed as iTEPs. These iTEPs not only are humorally tolerant but also possess a phase transition property. We further demonstrated that an amphiphilic iTEP copolymer self-assembles into a nanoparticle. The nanoparticle, when used to deliver a model CTL peptide vaccine, improved the potency of the vaccine in comparison to CTL vaccines in free peptide or protein forms.

Adverse immunogenicity of the peptide and protein materials could compromise their functionality by blocking the materials' interactions with their targets, shortening their half-lives,^(52, 53) and decreasing their bioavailability.⁽⁵⁴⁾ Immunogenicity can also be life-

threatening.⁽⁵⁴⁾ In the case of CTL vaccine delivery, it was suggested that humoral responses against vaccine carriers impede the effectiveness of their vaccine payloads.^(55, 56) Since our motivation in this study is to explore ELPs' potential as CTL vaccine carriers, we started the study by creating iTEPs so that immunogenicity of these polypeptide would not be a hurdle for their usage as the carriers. The need of creating iTEPs was substantiated by a very recent report showing that ELPs having distinct sequences displayed very different humoral immunogenicity when they were complexed with plasmid DNAs.⁽²²⁾ To create iTEPs, we took an unconventional polypeptide design and engineering practice that incorporates both functionality and immunogenicity criteria in the design. This practice was to minimize the risk that a material with a well characterized function may become valueless due to its afterward discovered adverse immunogenicity. This practice, indeed, has proven fruitful to our purpose. We have generated four sets of iTEPs which have desired low immunogenicity.

Besides as a proof-of-principle for the new ELP development practice, the success of generating these iTEPs has a practical significance. These iTEPs are unique and likely more valuable in preclinical and clinical applications than other reported ELPs because they were designed as immune tolerant materials to both mice and humans, which is unprecedented.^(18–21) Currently, iTEPs' immune tolerance in mice has been confirmed. Because the underlying ideas to render the iTEPs immune tolerated by mice and humans are the same, it is plausible that these iTEPs will be tolerated by human immunity when they are tested.

One of our overarching goals is to apply our new practice to the development of immune tolerant or immunogenic polypeptide materials beyond ELPs. While this goal can only be fully achieved after a broader investigation using additional model polypeptides, our results to some extent affirmed our criteria of designing non-immunogenic polypeptides. It is interesting that the iTEPs tested were found non-immunogenic regardless of their aggregation statuses or their nature as repetitive sequences, two auxiliary factors that were reported to possibly boost immunogenicity of polypeptides and proteins.^(51, 57, 58) The result is consistent with the notion that iTEPs likely do not contain BCR or TCR epitopes, or both. If a polypeptide doesn't consist of BCR or TCR epitopes, it should not induce humoral responses even when those auxiliary factors favor such. More significantly, because two different strategies were utilized to diminish potential immunogenicity of iTEPs' junction sequences, our results regarding the immunogenicity of iTEPs also suggest that both strategies are valid and will likely be useful to generate other immune tolerant polypeptides. To further establish our strategy to design polypeptide materials with pinpointed immunogenicity, we are employing the same strategy in an opposite way to generate immunogenic ELPs.

The iTEPs discovered in this study possess the characteristic phase transition of ELPs without having their typical VPGXG motif. On the one hand, it is reasonable because we did not limit iTEP design to the motif. We reasoned that generating an immune tolerant ELP for both humans and mice is more important to the goal of the study than generating an ELP fitting in with the motif, although the two needs are not necessarily mutually exclusive. On the other hand, this result may lead to a shift of the paradigm on the relationship between the VPGXG motif and the phase transition.⁽⁵⁹⁾ The fact that we were able to invent new ELPs

outside of the conventional VPGXG motif offers us a greater freedom and power to create novel and functional ELPs in the future.

ELPs have been widely tested in biomedical applications, and they certainly can assemble into nanostructures that can be good carriers for vaccines.^(26, 60–67) However, ELPs have not been used as CTL vaccine carriers. Here, we showed that an iTEP NP actually boosted the potency of the vaccines it delivered. This result suggests a new horizon for utilizing ELPs in vaccines and immunotherapy. This could be further substantiated if we can pinpoint immunogenicity of ELPs depending on their potential applications. For example, if we can generate both immunogenic and nonimmunogenic ELPs and their corresponding carriers, we could use this pair of otherwise very similar carriers to elucidate how the immunogenicity of carriers affect the potency of their vaccines or other immunotherapeutics payloads, which has not been clarified so far. In summary, an ability to precisely control the immunogenicity and functionality of ELPs is important to using the materials in delivering immunotherapeutics, which is still at its infancy.⁽⁶⁸⁾

4. Conclusion

We have successfully created four sets of non-canonical ELPs (iTEPs) that possess the inverse phase transition property and are immune-tolerated by mice. The success validates our mechanistic understanding about the phase transition and immunogenicity of ELPs. These iTEPs may be used for many reported biomedical applications of ELPs and possess an advantage for being non-immunogenic. Importantly, our study also demonstrated, for the first time, that ELPs can be used as CTL vaccine carriers, a very important but previously untested medical application. Most significantly, our novel polypeptide development practice, which places an equal design emphasis on functionality and immunogenicity, will help to avoid squandering efforts on developing functional ELPs that turn out to be immunogenic.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank Dr. Sung Wan Kim for the DLS measurements in his lab. Dr. James Marvin and Chris Leukel at the University of Utah Flow Cytometry Core provided technical assistance. The authors would also express their appreciation to Dr. Andrew Ramstead for his comments and suggestions on the manuscript, Dr. Kenneth Rock for CD2.4 cells, and Dr. Nilabh Shastri for B3Z cells. The work is supported by the University of Utah Start-up Fund, University of Utah Seed Grant, and NIH R00CA153929 to M.C.

Reference

1. Robinson HL, Amara RR. T cell vaccines for microbial infections. *Nat Med.* 2005; 11:s25–s32. [PubMed: 15812486]
2. Epstein JE, Tewari K, Lyke KE, Sim BKL, Billingsley PF, Laurens MB, et al. Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8+ T Cell Immunity. *Science.* 2011; 334:475–480. [PubMed: 21903775]
3. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? *Immunological Reviews.* 2011; 239:27–44. [PubMed: 21198663]

4. Schumacher R, Amacker M, Neuhaus D, Rosenthal R, Groeper C, Heberer M, et al. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26–35) peptide encapsulated into virosomes in vitro. *Vaccine*. 2005; 23:5572–5582. [PubMed: 16165256]
5. Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design WIREs. *Nanomed Nanobiotechnol*. 2011; 3:174–196.
6. Goldberg, Michael S. Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy. *Cell*. 2015; 161:201–204. [PubMed: 25860604]
7. Sahdev P, Ochyl L, Moon J. Biomaterials for Nanoparticle Vaccine Delivery Systems. *Pharm Res*. 2014; 31:2563–2582. [PubMed: 24848341]
8. Dreher MR, Simnick AJ, Fischer K, Smith RJ, Patel A, Schmidt M, et al. Temperature triggered self-assembly of polypeptides into multivalent spherical micelles. *J Am Chem Soc*. 2008; 130:687–694. [PubMed: 18085778]
9. Hassouneh W, Fischer K, MacEwan SR, Branscheid R, Fu CL, Liu R, et al. Unexpected multivalent display of proteins by temperature triggered self-assembly of elastin-like polypeptide block copolymers. *Biomacromolecules*. 2012; 13:1598–1605. [PubMed: 22515311]
10. Scheller J, Leps M, Conrad U. Forcing single-chain variable fragment production in tobacco seeds by fusion to elastin-like polypeptides. *Plant biotechnology journal*. 2006; 4:243–249. [PubMed: 17177800]
11. Alexander J, Oseroff C, Dahlberg C, Qin M, Ishioka G, Beebe M, et al. A decapeptide polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. *J Immunol*. 2002; 168:6189–6198. [PubMed: 12055232]
12. Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. *Vaccine*. 2001; 19:4652–4660. [PubMed: 11535313]
13. Thomson SA, Khanna R, Gardner J, Burrows SR, Coupar B, Moss DJ, et al. Minimal epitopes expressed in a recombinant polypeptide protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. *Proceedings of the National Academy of Sciences of the United States of America*. 1995; 92:5845–5849. [PubMed: 7541138]
14. Hassouneh W, Christensen T, Chilkoti A. Elastin-like polypeptides as a purification tag for recombinant proteins *Current protocols in protein science / editorial board*. John E. Coligan ... [et al.]. 2010; Chapter 6(Unit 6):11.
15. Da Silva DM, Pastrana DV, Schiller JT, Kast WM. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. *Virology*. 2001; 290:350–360. [PubMed: 11883199]
16. Ruedl C, Schwarz K, Jegerlehner A, Storni T, Manolova V, Bachmann MF. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. *J Virol*. 2005; 79:717–724. [PubMed: 15613299]
17. Liu XS, Xu Y, Hardy L, Khammanivong V, Zhao W, Fernando GJ, et al. IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. *J Immunol*. 2003; 171:4765–4772. [PubMed: 14568953]
18. Urry DW, Parker TM, Reid MC, Gowda DC. Biocompatibility of the Bioelastic Materials, Poly(GVGVP) and Its γ -Irradiation Cross-Linked Matrix: Summary of Generic Biological Test Results. *Journal of Bioactive and Compatible Polymers*. 1991; 6:263–282.
19. Urry, DW.; Pattanaik, A.; Accavitti, MA.; Luan, C.; McPherson, DT.; Xu, J., et al. *Handbook of Biodegradable Polymers*. Domb, AJ.; Kost, J.; Wiseman, DM., editors. CRC Press; 1998.
20. Christiansen, M.; Matson, M.; Brazg, RL.; Georgopoulos, L.; Arnold, S.; Kramer, W., et al. *Weekly Subcutaneous Doses of Glymera (PB1023) a Novel GLP-1 Analogue Reduce Glucose Exposure Dose-Dependently*. Philadelphia, Pennsylvania: 2012.
21. Cappello, J. *Handbook of Biodegradable Polymers*. Domb, AJ.; Kost, J.; Wiseman, DM., editors. Amsterdam: Harwood Academic Publishers; 1997. p. 387-416.
22. Nouri F, Wang X, Chen X, Hatefi A. Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like. *Peptides Pharm Res*. 2015:1–11.

23. Moreland LW, McCabe DP, Caldwell JR, Sack M, Weisman M, Henry G, et al. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. *The Journal of rheumatology*. 2000; 27:601–609. [PubMed: 10743796]
24. Rau R, Sander O, van Riel P, van de Putte L, Hasler F, Zaug M, et al. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. *The Journal of rheumatology*. 2003; 30:680–690. [PubMed: 12672184]
25. Urry DW. Free energy transduction in polypeptides and proteins based on inverse temperature transitions. *Progress in biophysics and molecular biology*. 1992; 57:23–57. [PubMed: 1549698]
26. MacEwan SR, Chilkoti A. Elastin-like polypeptides: Biomedical applications of tunable biopolymers. *Peptide Science*. 2010; 94:60–77. [PubMed: 20091871]
27. McDaniel JR, Mackay JA, Quiroz FG, Chilkoti A. Recursive directional ligation by plasmid reconstruction allows rapid and seamless cloning of oligomeric genes. *Biomacromolecules*. 2010; 11:944–952. [PubMed: 20184309]
28. Rock KL, Fleischacker C, Gamble S. Peptide-priming of cytolytic T cell immunity in vivo using beta 2-microglobulin as an adjuvant. *The Journal of Immunology*. 1993; 150:1244–1252. [PubMed: 8381832]
29. Zhao P, Dong S, Bhattacharyya J, Chen M. iTEP Nanoparticle-Delivered Salinomycin Displays an Enhanced Toxicity to Cancer Stem Cells in Orthotopic Breast Tumors. *Molecular pharmaceutics*. 2014
30. Lee C, Levin A, Branton D. Copper staining: a five-minute protein stain for sodium dodecyl sulfate-polyacrylamide gels. *Analytical biochemistry*. 1987; 166:308–312. [PubMed: 2449094]
31. Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. *J Immunol Methods*. 1998; 221:35–41. [PubMed: 9894896]
32. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. *The Journal of Immunology*. 1997; 158:2723–2730. [PubMed: 9058806]
33. Karttunen J, Sanderson S, Shastri N. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. *Proceedings of the National Academy of Sciences*. 1992; 89:6020–6024.
34. Bernard A, Coitot S, Bremont A, Bernard G. T and B cell cooperation: a dance of life and death. *Transplantation*. 2005; 79:S8–S11. [PubMed: 15699753]
35. Parker DC. T cell-dependent B cell activation. *Annual review of immunology*. 1993; 11:331–360.
36. Murphy, K. *Janeway's Immunobiology*. Garland Science; 2012.
37. VanRegenmortel, MH. *Structure of Antigens*. VanRegenmortel, MH., editor. CRC Press; 1992. p. 1-28.
38. Antigenicity MS. some molecular aspects. *Science*. 1969; 166
39. Murphy, K. *Janeway's Immunobiology*. Garland Science; 2012. p. 888
40. Liu W, Peng Z, Liu Z, Lu Y, Ding J, Chen YH. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. *Vaccine*. 2004; 23:366–371. [PubMed: 15530682]
41. Kovacs-Nolan J, Mine Y. Tandem copies of a human rotavirus VP8 epitope can induce specific neutralizing antibodies in BALB/c mice. *Biochimica et biophysica acta*. 2006; 1760:1884–1893. [PubMed: 16978788]
42. Partidos C, Stanley C, Steward M. The influence of orientation and number of copies of T and B cell epitopes on the specificity and affinity of antibodies induced by chimeric peptides. *European journal of immunology*. 1992; 22:2675–2680. [PubMed: 1382995]
43. Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. *Proc Natl Acad Sci U S A*. 2008; 105:11311–11316. [PubMed: 18678888]
44. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, et al. Characterization of the B cell epitopes associated with a truncated form of *Pseudomonas* exotoxin (PE38) used to make

- immunotoxins for the treatment of cancer patients. *Journal of immunology* (Baltimore, Md. : 1950). 2006; 177:8822–8834.
45. MacEwan SR, Chilkoti A. Elastin-like polypeptides: biomedical applications of tunable biopolymers. *Biopolymers*. 2010; 94:60–77. [PubMed: 20091871]
46. Smejkal GB. The Coomassie chronicles: past, present and future perspectives in polyacrylamide gel staining. *Expert review of proteomics*. 2004; 1:381–387. [PubMed: 15966833]
47. Creighton, TE. *Proteins: Structures and Molecular Properties*. W.H. Freeman Company; 1993.
48. Urry DW, Luan CH, Parker TM, Gowda DC, Prasad KU, Reid MC, Safavy A. Temperature of Polypeptide Inverse Temperature Transition Depends on Mean Residue Hydrophobicity. *J. Am. chem. Soc.* 1991; 113:3.
49. Meyer DE, Chilkoti A. Quantification of the effects of chain length and concentration on the thermal behavior of elastin-like polypeptides. *Biomacromolecules*. 2004; 5:846–851. [PubMed: 15132671]
50. Jefferis R. Aggregation, immune complexes and immunogenicity mAbs. 2011; 3:503–504.
51. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. *The AAPS journal*. 2006; 8:E501–E507. [PubMed: 17025268]
52. Zhou L, Hoofring S, Wu Y, Vu T, Ma P, Swanson S, et al. Stratification of Antibody-Positive Subjects by Antibody Level Reveals an Impact of Immunogenicity on Pharmacokinetics. *The AAPS journal*. 2013; 15:30–40. [PubMed: 23054969]
53. Kontos S, Hubbell JA. Drug development: longer-lived proteins. *Chemical Society reviews*. 2012; 41:2686–2695. [PubMed: 22310725]
54. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. *Trends in immunology*. 2007; 28:482–490. [PubMed: 17964218]
55. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products. 2013
56. Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. *Trends in biotechnology*. 2006; 24:274–280. [PubMed: 16631266]
57. Bachmann MF, Zinkernagel RM. NEUTRALIZING ANTIVIRAL B CELL RESPONSES. *Annual Review of Immunology*. 1997; 15:235–270.
58. Feldmann M, Basten A. THE RELATIONSHIP BETWEEN ANTIGENIC STRUCTURE AND THE REQUIREMENT FOR THYMUS-DERIVED CELLS IN THE IMMUNE RESPONSE. *The Journal of Experimental Medicine*. 1971; 134:103–119. [PubMed: 4104294]
59. Urry DW. Physical Chemistry of Biological Free Energy Transduction As Demonstrated by Elastic Protein-Based Polymers. *Journal of Physical Chemistry B*. 1997; 101:11007–11028.
60. Chilkoti A, Dreher MR, Meyer DE, Raucher D. Targeted drug delivery by thermally responsive polymers. *Adv Drug Deliv Rev*. 2002; 54:613–630. [PubMed: 12204595]
61. Liu J, Bauer H, Callahan J, Kopeckova P, Pan H, Kopecek J. Endocytic uptake of a large array of HPMA copolymers: Elucidation into the dependence on the physicochemical characteristics. *J Control Release*. 2010; 143:71–79. [PubMed: 20043962]
62. MacKay JA, Chen M, McDaniel JR, Liu W, Simnick AJ, Chilkoti A. Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. *Nat Mater*. 2009; 8:993–999. [PubMed: 19898461]
63. Shi P, Aluri S, Lin YA, Shah M, Edman M, Dhandhukia J, et al. Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo. *Journal of controlled release : official journal of the Controlled Release Society*. 2013; 171:330–338. [PubMed: 23714121]
64. Bidwell GL 3rd, Perkins E, Hughes J, Khan M, James JR, Raucher D. Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. *PloS one*. 2013; 8:e55104. [PubMed: 23372821]
65. Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. *Drug discovery today*. 2013; 18:807–817. [PubMed: 23726889]

66. Le DH, Hanamura R, Pham DH, Kato M, Tirrell DA, Okubo T, et al. Self-assembly of elastin-mimetic double hydrophobic polypeptides. *Biomacromolecules*. 2013; 14:1028–1034. [PubMed: 23495825]
67. Benitez PL, Sweet JA, Fink H, Chennazhi KP, Nair SV, Enejder A, et al. Sequence-specific crosslinking of electrospun, elastin-like protein preserves bioactivity and native-like mechanics. *Advanced healthcare materials*. 2013; 2:114–118. [PubMed: 23184558]
68. Garcia-Arevalo C, Bermejo-Martin JF, Rico L, Iglesias V, Martin L, Rodriguez-Cabello JC, et al. Immunomodulatory nanoparticles from elastin-like recombinamers: single-molecules for tuberculosis vaccine development. *Mol Pharm*. 2013; 10:586–597. [PubMed: 23301613]

Figure 1.

An outline of iTEP monomers obtained from a homology analysis between mouse tropoelastin and human elastin. Blue and red letters indicate amino acids from mouse and human elastins, respectively. Green letters indicate the same amino acids across both species. The numbers indicate the positions of these building blocks in their parent elastin proteins.

Figure 2.
 (A) Schematics showing the approach to double the length of the coding genes of iTEPs. (B) iTEP coding genes on agarose gel after they were cleaved from pET25b(+) vector by XbaI and BamHI. Sizes of these iTEP genes confirmed they have the right lengths, suggesting these genes would code iTEPs of expected lengths. (C) SDS-PAGE gel showing MWs and purity of individual iTEPs.

Figure 3.

(A–D) Turbidity profiles (OD₃₅₀) of iTEP_A, iTEP_B, iTEP_C, and iTEP_D as they were heated and then cooled between 20 °C and 80 °C. (E) The turbidity profiles of iTEP_B in 2.5M NaCl as a function of temperature. Each curve represented an average of three measurements.

Figure 4.

(A) The immunization schedule and the time point of the assessment of humoral responses. (B) The summary of IgG titers of OVA, MSA, and iTEP-immunized mice. Each dot represents one mouse's result. The medians and interquartile ranges of the titers are shown. (C–F) Absorbance (OD_{450}) of sera that were collected from iTEP_A (C), iTEP_B (D), iTEP_C (E), and iTEP_D (F) immunized mice after they were diluted and assayed by ELISA. Each data point corresponds to the mean value of three absorbance measurements per serum.

dilution. The data of each mouse were linked together with a line. The cut-off ranges for positive absorbance values were shown as a blue shade.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 5.

(A) Schematics showing that the $iTEP_B$ - $iTEP_A$ -pOVA fusion self-assembles into a NP. (B) SDS-PAGE gel showing MWs and purity of two fusions, $iTEP_B$ -pOVA and $iTEP_B$ - $iTEP_A$ -pOVA. (C) Turbidity profile of the $iTEP_B$ - $iTEP_A$ -pOVA fusion as a function of temperature. The solution has a sharp increase of the turbidity at 70 $^{\circ}$ C indicating the formation of aggregates at that temperature. Before that, there is a slow, mild increase of turbidity suggesting the formation of micelles⁽⁸⁾ (D) Size distributions of the $iTEP_B$ -pOVA and $iTEP_B$ - $iTEP_A$ -pOVA fusions (25 μ M) obtained from DLS measurement. (E) A

representative micrograph of a negatively stained iTEP_B-iTEP_A-pOVA fusion confirming the NP size of the fusion.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 6.

(A) Presentation of SIINFEKL by DC 2.4 cells after the SIINFEKL was delivered by OVA, soluble iTEP_B-pOVA fusion, or iTEP-pOVA NP. Data are presented as means of normalized MFI $\pm$ SD of the entire DC population used in the experiments ($n = 4$ independent experiments). (B) Activation of B3Z cells after they were incubated with DCs that presented SIINFEKL. The DCs were pre-incubated with different forms of antigens as noted in the picture. Data are presented as mean $\pm$ SD 3 independent experiments). (C) *Ex vivo* analysis of active, SIINFEKL-restricted splenocytes cells from mice ($n=3-5$)

immunized with OVA, free SIINFEKL peptide, or iTEP-pOVA NP. The activation of the cells was characterized by using an INF- γ -based ELISPOT assay. Data were presented as Spot Forming Units (SFU)/million cells $\pm$ SD. For all panels, ★ indicates $p < 0.05$, t -test between the paired treatments.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

The sequences, MW, transition temperatures of iTEPs

iTEP	Construct sequence	MW	Tt (heating)	Tt (cooling)	Relative Hydrophobicity
iTEP _A	G(GVLPGVG) ₂₈ GG	16.6 kDa	33.30 ± 0.09°C	29.70 ± 0.05°C	High
iTEP _B	G(GAGVPG) ₇₀ GG	32.1 kDa	65.45* ± 0.15°C	60.85* ± 0.44°C	Low
iTEP _C	G(VPGFGAGAG) ₂₁ GG	15.3 kDa	35.70 ± 0.58°C	34.00 ± 0.58°C	High
iTEP _D	G(VPGLGAGAG) ₆₆ GG	65.6 kDa	38.60 ± 1.20°C	35.20 ± 0.57°C	High
iTEP _B -iTEP _A -pOVA	G(GAGVPG) ₇₀ G(GVLPGVG) ₂₈ G(ESIINFELT) ₂ GG	49.7 kDa	75.40 ± 0.14°C	73.70 ± 0.23°C	(N/A)

The Tt data presented in the table were obtained from experiments with sample's concentrations at 25 μM in H₂O except for iTEPB.

*The Tts of iTEPB was measured in the presence of 2.5 M NaCl.